<?xml version='1.0' encoding='utf-8'?>
<document id="20110052"><sentence text="Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors: a prospective, multicenter, open-label, randomized, two-way crossover drug-drug interaction study."><entity charOffset="30-42" id="DDI-PubMed.20110052.s1.e0" text="ketoconazole" /><entity charOffset="91-101" id="DDI-PubMed.20110052.s1.e1" text="bortezomib" /><pair ddi="false" e1="DDI-PubMed.20110052.s1.e0" e2="DDI-PubMed.20110052.s1.e0" /><pair ddi="false" e1="DDI-PubMed.20110052.s1.e0" e2="DDI-PubMed.20110052.s1.e1" /></sentence><sentence text="The proteasome inhibitor bortezomib undergoes oxidative biotransformation via multiple cytochrome P450 (CYP) enzymes, with CYP3A4 identified as a partial, yet potentially important, contributor based on in vitro drug metabolism studies"><entity charOffset="25-35" id="DDI-PubMed.20110052.s2.e0" text="bortezomib" /></sentence><sentence text="" /><sentence text="The aim of this study was to assess the effect of concomitant administration of ketoconazole on the pharmacokinetics (PK) and pharmacodynamics (PD) of bortezomib"><entity charOffset="80-92" id="DDI-PubMed.20110052.s4.e0" text="ketoconazole" /><entity charOffset="151-161" id="DDI-PubMed.20110052.s4.e1" text="bortezomib" /><pair ddi="false" e1="DDI-PubMed.20110052.s4.e0" e2="DDI-PubMed.20110052.s4.e0" /><pair ddi="false" e1="DDI-PubMed.20110052.s4.e0" e2="DDI-PubMed.20110052.s4.e1" /></sentence><sentence text="" /><sentence text="This was a prospective, multicenter, open-label, randomized, multiple-dose, 2-way crossover study in patients with advanced solid tumors" /><sentence text=" All patients received bortezomib 1"><entity charOffset="23-33" id="DDI-PubMed.20110052.s7.e0" text="bortezomib" /></sentence><sentence text="0 mg/m(2) IV (on days 1, 4, 8, and 11 of two 21-day cycles) and were randomized to receive concomitant ketoconazole 400 mg on days 6, 7, 8, and 9 of cycle 1 or 2"><entity charOffset="103-115" id="DDI-PubMed.20110052.s8.e0" text="ketoconazole" /></sentence><sentence text=" Serial blood samples were collected over the day-8 dosing interval (immediately prior to bortezomib administration, and from 5 minutes to 72 hours after administration) in cycles 1 and 2 for measurement of plasma bortezomib concentrations for noncompartmental PK analysis and blood 20S proteasome inhibition for PD analysis"><entity charOffset="90-100" id="DDI-PubMed.20110052.s9.e0" text="bortezomib" /><entity charOffset="214-224" id="DDI-PubMed.20110052.s9.e1" text="bortezomib" /><pair ddi="false" e1="DDI-PubMed.20110052.s9.e0" e2="DDI-PubMed.20110052.s9.e0" /><pair ddi="false" e1="DDI-PubMed.20110052.s9.e0" e2="DDI-PubMed.20110052.s9.e1" /></sentence><sentence text=" All adverse events (AEs) were recorded during each cycle including serious AEs and all neurotoxicity events for up to 30 days after the last dose of bortezomib"><entity charOffset="150-160" id="DDI-PubMed.20110052.s10.e0" text="bortezomib" /></sentence><sentence text="" /><sentence text="Twenty-one patients (median age, 57 years; sex, 67% male; race, 86% white; median body surface area, 2" /><sentence text="01 m(2)) were randomized to treatment" /><sentence text=" Twelve patients completed the protocol-specified dosing and PK sampling in both cycles 1 and 2" /><sentence text=" Assessment of the effect of ketoconazole on bortezomib PK and PD was based on data in these 12 PK-evaluable patients"><entity charOffset="29-41" id="DDI-PubMed.20110052.s15.e0" text="ketoconazole" /><entity charOffset="45-55" id="DDI-PubMed.20110052.s15.e1" text="bortezomib" /><pair ddi="false" e1="DDI-PubMed.20110052.s15.e0" e2="DDI-PubMed.20110052.s15.e0" /><pair ddi="false" e1="DDI-PubMed.20110052.s15.e0" e2="DDI-PubMed.20110052.s15.e1" /></sentence><sentence text=" The ratio of geometric mean bortezomib AUC(0-tlast)(AUC from time 0 to last quantifiable concentration) for bortezomib plus ketoconazole versus bortezomib alone was 1"><entity charOffset="109-119" id="DDI-PubMed.20110052.s16.e0" text="bortezomib" /><entity charOffset="125-137" id="DDI-PubMed.20110052.s16.e1" text="ketoconazole" /><entity charOffset="145-155" id="DDI-PubMed.20110052.s16.e2" text="bortezomib" /><pair ddi="false" e1="DDI-PubMed.20110052.s16.e0" e2="DDI-PubMed.20110052.s16.e0" /><pair ddi="false" e1="DDI-PubMed.20110052.s16.e0" e2="DDI-PubMed.20110052.s16.e1" /><pair ddi="false" e1="DDI-PubMed.20110052.s16.e0" e2="DDI-PubMed.20110052.s16.e2" /><pair ddi="false" e1="DDI-PubMed.20110052.s16.e1" e2="DDI-PubMed.20110052.s16.e1" /><pair ddi="false" e1="DDI-PubMed.20110052.s16.e1" e2="DDI-PubMed.20110052.s16.e2" /></sentence><sentence text="352 (90% CI, 1" /><sentence text="032-1" /><sentence text="772)" /><sentence text=" Consistent with this observed mean increase in bortezomib exposure, concomitant administration of ketoconazole was associated with a corresponding increase (24%-46%) in the blood proteasome inhibitory effect"><entity charOffset="48-58" id="DDI-PubMed.20110052.s20.e0" text="bortezomib" /><entity charOffset="99-111" id="DDI-PubMed.20110052.s20.e1" text="ketoconazole" /><pair ddi="false" e1="DDI-PubMed.20110052.s20.e0" e2="DDI-PubMed.20110052.s20.e0" /><pair ddi="false" e1="DDI-PubMed.20110052.s20.e0" e2="DDI-PubMed.20110052.s20.e1" /></sentence><sentence text="" /><sentence text="Concomitant administration of the CYP3A inhibitor ketoconazole with bortezomib resulted in a mean increase of 35% in bortezomib exposure"><entity charOffset="50-62" id="DDI-PubMed.20110052.s22.e0" text="ketoconazole" /><entity charOffset="68-78" id="DDI-PubMed.20110052.s22.e1" text="bortezomib" /><entity charOffset="117-127" id="DDI-PubMed.20110052.s22.e2" text="bortezomib" /><pair ddi="false" e1="DDI-PubMed.20110052.s22.e0" e2="DDI-PubMed.20110052.s22.e0" /><pair ddi="false" e1="DDI-PubMed.20110052.s22.e0" e2="DDI-PubMed.20110052.s22.e1" /><pair ddi="false" e1="DDI-PubMed.20110052.s22.e0" e2="DDI-PubMed.20110052.s22.e2" /><pair ddi="false" e1="DDI-PubMed.20110052.s22.e1" e2="DDI-PubMed.20110052.s22.e1" /><pair ddi="false" e1="DDI-PubMed.20110052.s22.e1" e2="DDI-PubMed.20110052.s22.e2" /></sentence><sentence text=" ClinicalTrials" /><sentence text="gov identifier: NCT00129207" /><sentence text="" /></document>